ReviewFrontiers in pharmacology2026
Predictive biomarkers for precision treatment in rheumatoid arthritis: are we there yet?
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population and is associated with a substantial reduction in both life expectancy and quality of life. Although current treatments, primarily disease-modifying antirheumatic drugs, have been shown to suppress inflammation, clinical responses vary widely between individuals, reflecting the heterogeneity of the disease. Consequently, identifying reliable biomarkers to predict therapeutic response has become a key priority for improving clinical management. In this focused review, we summarise recent advances in the discovery of predictive biomarkers for RA and compare their reported specificity and sensitivity using published data. We also highlight key limitations in the existing literature that undermine reproducibility in this field. Coordinated efforts across the rheumatology community to address these challenges will be essential to translate biomarker research into personalised treatment strategies for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.